WO1998018931A2
(en)
*
|
1996-10-31 |
1998-05-07 |
Human Genome Sciences, Inc. |
Streptococcus pneumoniae polynucleotides and sequences
|
US6676943B1
(en)
|
1997-04-24 |
2004-01-13 |
Regents Of The University Of Minnesota |
Human complement C3-degrading protein from Streptococcus pneumoniae
|
US6800744B1
(en)
|
1997-07-02 |
2004-10-05 |
Genome Therapeutics Corporation |
Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
|
US7153952B1
(en)
|
1997-07-02 |
2006-12-26 |
sanofi pasteur limited/sanofi pasteur limitée |
Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
|
HU228497B1
(en)
|
1998-02-20 |
2013-03-28 |
Id Biomedical Corp Quebec |
Group b steptococcus antigens
|
ATE461709T1
(de)
*
|
1998-04-07 |
2010-04-15 |
Medimmune Llc |
Choline-bindende proteine derivate aus pneumokoken als impfstoff
|
EP1098980B1
(en)
|
1998-07-22 |
2014-09-03 |
Stichting Dienst Landbouwkundig Onderzoek |
Streptococcus suis vaccines and diagnostic tests
|
US20030134407A1
(en)
|
1998-07-27 |
2003-07-17 |
Le Page Richard William Falla |
Nucleic acids and proteins from Streptococcus pneumoniae
|
EP1801218A3
(en)
*
|
1998-07-27 |
2007-10-10 |
Sanofi Pasteur Limited |
Nucleic acids and proteins from streptococcus pneumoniae
|
PT2261358E
(pt)
*
|
1998-12-23 |
2014-07-30 |
Id Biomedical Corp Quebec |
Antigénios de streptococcus
|
EP1950302B1
(en)
|
1998-12-23 |
2012-12-05 |
ID Biomedical Corporation of Quebec |
Streptococcus antigens
|
US7128918B1
(en)
*
|
1998-12-23 |
2006-10-31 |
Id Biomedical Corporation |
Streptococcus antigens
|
JP4846906B2
(ja)
*
|
1999-03-19 |
2011-12-28 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ワクチン
|
US6887480B1
(en)
*
|
1999-06-10 |
2005-05-03 |
Medimmune, Inc. |
Streptococcus pneumoniae proteins and vaccines
|
JP2004503565A
(ja)
*
|
2000-06-14 |
2004-02-05 |
サイトヴァックス・バイオテクノロジーズ・インコーポレーテッド |
構造特異的ペプチドを生産するためのコイルドコイル構造的骨格の使用
|
TR200704553T2
(tr)
*
|
2000-06-20 |
2007-11-21 |
Id Biomedical Corporation |
Streptokok antijenleri.
|
US7074415B2
(en)
*
|
2000-06-20 |
2006-07-11 |
Id Biomedical Corporation |
Streptococcus antigens
|
GB0022742D0
(en)
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
DE60239858D1
(de)
|
2001-02-02 |
2011-06-09 |
Stichting Dienst Landbouwkundi |
Umwelt-regulierte gene, welche an der virulenz von streptococcus suis beteiligt sind
|
EP1456231A2
(en)
*
|
2001-12-20 |
2004-09-15 |
Shire Biochem Inc. |
Streptococcus antigens
|
US8229903B2
(en)
*
|
2002-12-19 |
2012-07-24 |
International Business Machines Corporation |
Suggesting data interpretations and patterns for updating policy documents
|
US9931397B2
(en)
|
2005-06-27 |
2018-04-03 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
EP1754717A1
(en)
|
2005-08-19 |
2007-02-21 |
Université de Lausanne |
Antigenic peptides and their use
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CN101378778B
(zh)
*
|
2005-12-22 |
2013-02-06 |
葛兰素史密丝克莱恩生物有限公司 |
肺炎球菌多糖缀合物疫苗
|
PT2097102E
(pt)
|
2006-09-07 |
2012-08-03 |
Glaxosmithkline Biolog Sa |
Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
|
US8128939B2
(en)
|
2007-04-13 |
2012-03-06 |
The Board Of Regents Of The University Of Oklahoma |
Mutants of cholesterol-dependent cytolysins and uses thereof
|
US20100074918A1
(en)
|
2007-05-02 |
2010-03-25 |
Jan Poolman |
Vaccine
|
AU2008267208B2
(en)
|
2007-06-26 |
2012-01-19 |
Glaxosmithkline Biologicals S.A. |
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
|
CN101802198B
(zh)
*
|
2007-07-23 |
2016-02-17 |
圣诺菲·帕斯图尔有限公司 |
免疫原性多肽和单克隆抗体
|
US20160228500A9
(en)
*
|
2007-07-23 |
2016-08-11 |
Martina Ochs |
Immunogenic Polypeptides and Monoclonal Antibodies
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
EP2023143A1
(en)
*
|
2007-08-06 |
2009-02-11 |
Boehringer Ingelheim Vetmedica Gmbh |
Immunogenic streptococcus proteins
|
CA2716706C
(en)
|
2008-03-03 |
2014-02-18 |
Irm Llc |
Compounds and compositions as tlr activity modulators
|
RS54306B1
(en)
|
2008-04-16 |
2016-02-29 |
Glaxosmithkline Biologicals S.A. |
THE VACCINE
|
AU2009296458A1
(en)
|
2008-09-26 |
2010-04-01 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
JP5668049B2
(ja)
|
2009-03-24 |
2015-02-12 |
ノバルティス アーゲー |
髄膜炎菌h因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
|
BRPI1014494A2
(pt)
|
2009-04-30 |
2016-08-02 |
Coley Pharm Group Inc |
vacina pneumocócica e usos da mesma
|
WO2010132833A1
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
US9517263B2
(en)
|
2009-06-10 |
2016-12-13 |
Glaxosmithkline Biologicals Sa |
Benzonaphthyridine-containing vaccines
|
BR112012004806B8
(pt)
|
2009-09-02 |
2022-10-04 |
Novartis Ag |
composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
|
JO3257B1
(ar)
|
2009-09-02 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات كمعدلات لفاعلية tlr
|
NZ620441A
(en)
|
2009-09-03 |
2015-08-28 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
SG178904A1
(en)
|
2009-09-10 |
2012-04-27 |
Novartis Ag |
Combination vaccines against respiratory tract diseases
|
WO2011057148A1
(en)
|
2009-11-05 |
2011-05-12 |
Irm Llc |
Compounds and compositions as tlr-7 activity modulators
|
SG10201501980SA
(en)
|
2009-12-15 |
2015-05-28 |
Novartis Ag |
Homogeneous suspension of immunopotentiating compounds and uses thereof
|
US20130183350A1
(en)
*
|
2009-12-22 |
2013-07-18 |
Kevin Harper |
Immunogenic compositions
|
CN102939105B
(zh)
|
2009-12-22 |
2016-11-16 |
赛诺菲巴斯德有限公司 |
免疫原性组合物和相关的方法
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
JP5848748B2
(ja)
|
2010-03-23 |
2016-01-27 |
アイアールエム・リミテッド・ライアビリティ・カンパニーIrm,Llc |
感染症、炎症、呼吸器疾患などの処置に使用するtlr2アゴニストとしての化合物(システインベースのリポペプチド)および組成物
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
JP6046632B2
(ja)
|
2010-12-03 |
2016-12-21 |
サノフィ パストゥール リミテッドSanofi Pasteur Limited |
肺炎球菌に対する免疫用組成物
|
EP2680883B1
(en)
|
2011-03-02 |
2018-09-05 |
Pfizer Inc |
Pcsk9 vaccine
|
GB201103836D0
(en)
|
2011-03-07 |
2011-04-20 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
WO2012156391A1
(en)
|
2011-05-17 |
2012-11-22 |
Glaxosmithkline Biologicals S.A. |
Vaccine against streptococcus pneumoniae
|
JP2015510872A
(ja)
|
2012-03-07 |
2015-04-13 |
ノバルティス アーゲー |
Streptococcuspneumoniae抗原の増強された製剤
|
CA2899787A1
(en)
|
2013-02-01 |
2014-08-07 |
Glaxosmithkline Biologicals Sa |
Intradermal delivery of immunological compositions comprising toll-like receptor agonists
|
CA2900008A1
(en)
|
2013-02-07 |
2014-08-14 |
Children's Medical Center Corporation |
Protein antigens that provide protection against pneumococcal colonization and/or disease
|
SI3096786T1
(sl)
|
2014-01-21 |
2021-09-30 |
Pfizer Inc. |
Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
|
EP3616716A3
(en)
|
2014-01-21 |
2020-05-06 |
Pfizer Inc |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
JP6612260B2
(ja)
|
2014-01-21 |
2019-11-27 |
ファイザー・インク |
肺炎連鎖球菌(Streptococcus pneumoniae)莢膜多糖およびそのコンジュゲート
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US10668164B2
(en)
|
2014-02-14 |
2020-06-02 |
Pfizer Inc. |
Immunogenic glycoprotein conjugates
|
BR112017010696A2
(pt)
|
2014-11-21 |
2017-12-26 |
Univ Oklahoma |
mutantes de pneumolisina e métodos de utilização deste mutante
|
CN107427568B
(zh)
|
2015-01-15 |
2021-12-14 |
辉瑞公司 |
用于肺炎球菌疫苗中的免疫原性组合物
|
PE20240927A1
(es)
|
2015-07-21 |
2024-04-30 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CA3005524C
(en)
|
2015-11-20 |
2023-10-10 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
ES2911490T3
(es)
|
2017-01-20 |
2022-05-19 |
Pfizer |
Composiciones inmunogénicas para su uso en vacunas antineumocócicas
|
MX2020008417A
(es)
|
2018-02-12 |
2020-11-11 |
Inimmune Corp |
Ligandos de receptores de tipo toll.
|
CN112673054A
(zh)
|
2018-07-19 |
2021-04-16 |
葛兰素史密丝克莱恩生物有限公司 |
用于制备干燥多糖的方法
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP2022512345A
(ja)
|
2018-12-12 |
2022-02-03 |
ファイザー・インク |
免疫原性多重ヘテロ抗原多糖-タンパク質コンジュゲートおよびその使用
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
US20220184199A1
(en)
|
2019-04-10 |
2022-06-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
AU2020323498A1
(en)
|
2019-07-31 |
2022-03-03 |
Sk Bioscience Co., Ltd. |
Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
|
CA3159573A1
(en)
|
2019-11-01 |
2021-05-06 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP2021132644A
(ja)
|
2020-02-21 |
2021-09-13 |
ファイザー・インク |
糖の精製
|
PE20230170A1
(es)
|
2020-02-23 |
2023-02-01 |
Pfizer |
Composiciones de escherichia coli y sus metodos
|
CA3199094A1
(en)
|
2020-10-22 |
2022-04-28 |
Pfizer Inc. |
Methods for purifying bacterial polysaccharides
|
JP2023546615A
(ja)
|
2020-10-27 |
2023-11-06 |
ファイザー・インク |
大腸菌組成物およびその方法
|
WO2022096590A1
(en)
|
2020-11-04 |
2022-05-12 |
Eligo Bioscience |
Phage-derived particles for in situ delivery of dna payload into c. acnes population
|
AU2021373358A1
(en)
|
2020-11-04 |
2023-06-01 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022234416A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
JP2024517780A
(ja)
|
2021-05-03 |
2024-04-23 |
ファイザー・インク |
細菌およびベータコロナウイルス感染症に対するワクチン接種
|
MX2023013434A
(es)
|
2021-05-28 |
2023-12-12 |
Pfizer Inc |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
|
US20220387576A1
(en)
|
2021-05-28 |
2022-12-08 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2024084397A1
(en)
|
2022-10-19 |
2024-04-25 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
WO2024110839A2
(en)
|
2022-11-22 |
2024-05-30 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|